The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Oct. 29, 2019
Filed:
Jul. 18, 2014
Applicant:
Novo Nordisk A/s, Bagsvaerd, DK;
Inventors:
Jes Thorn Clausen, Hoeng, DK;
Berit Olsen Krogh, Roedovre, DK;
Helle Heibroch Petersen, Koebenhavn V, DK;
Cecilia Augustsson, Malmoe, DK;
Assignee:
Novo Nordisk A/S, Bagsvaerd, DK;
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/395 (2006.01); C07K 16/38 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/38 (2013.01); A61K 2039/505 (2013.01); C07K 2299/00 (2013.01); C07K 2317/30 (2013.01); C07K 2317/34 (2013.01); C07K 2317/55 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01);
Abstract
The present invention relates to an antibody that specifically binds to an epitope in the N-terminal part (residues 1 to 79) of tissue factor pathway inhibitor (TFPI). An antibody according to the invention may be capable of neutralising TFPI inhibition of the TF/FVIIa complex, even in the presence of elevated levels of TFPI. Such antibodies may find utility in the treatment of subjects with a coagulopathy, such as those with haemophilia A or B, with or without inhibitors.